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Abstract
Introduction Poly (ADP-ribose) polymerase (PARP)
participates in inflammation by cellular necrosis and the nuclear
factor-kappa-B (NF-κB)-dependent transcription. The purpose
of this study was to examine the roles of PARP in ventilator-
induced lung injury (VILI) in normal mice lung.
Methods Male C57BL/6 mice were divided into four groups:
sham tracheostomized (sham), lung-protective ventilation (LPV),
VILI, and VILI with PARP inhibitor PJ34 pretreatment
(PJ34+VILI) groups. Mechanical ventilation (MV) settings were
peak inspiratory pressure (PIP) 15 cm H2O + positive end-
expiratory pressure (PEEP) 3 cm H2O + 90 breaths per minute
for the LPV group and PIP 40 cm H2O + PEEP 0 cm H2O + 90
breaths per minute for the VILI and PJ34+VILI groups. After 2
hours of MV, acute lung injury (ALI) score, wet-to-dry (W/D)
weight ratio, PARP activity, and dynamic compliance (CD) were
recorded. Tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-
6), myeloperoxidase (MPO) activity, and nitrite/nitrate (NOX) in
the bronchoalveolar lavage fluid and NF-κB DNA-binding
activity in tissue homogenates were measured.
Results The VILI group showed higher ALI score, W/D weight
ratio, MPO activity, NOX, and concentrations of TNF-α and IL-6
along with lower CD than the sham and LPV groups (P < 0.05).
In the PJ34+VILI group, PJ34 pretreatment improved all
histopathologic ALI, inflammatory profiles, and pulmonary
dynamics (P < 0.05). NF-κB activity was increased in the VILI
group as compared with the sham and LPV groups (P < 0.05)
and was decreased in the PJ34+VILI group as compared with
the VILI group (P = 0.009). Changes in all parameters were
closely correlated with the PARP activity (P < 0.05).
Conclusion Overactivation of PARP plays an important role in
the inflammatory and transcriptional pathogenesis of VILI, and
PARP inhibition has potentially beneficial effects on the
prevention and treatment of VILI.
Introduction
Ventilator-induced lung injury (VILI) has been established as a
significant risk in patients receiving mechanical ventilation
(MV). The spectrum of VILI includes not only air leaks and
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increases in endothelial and epithelial permeability but also
increases in pulmonary and systemic inflammatory mediators
[1,2]. Although the lung-protective ventilation (LPV) strategy
has been shown to reduce VILI in patients with acute respira-
tory distress syndrome (ARDS) [3], the effectiveness of the
LPV strategy may be limited because of severe spatial hetero-
geneity of lung involvement resulting in incomplete prevention
of regional alveolar distension [4]. Alternative therapeutic
strategies based on a precise understanding of its pathophys-
iology are necessary to completely eliminate the iatrogenic
consequences of VILI.
Poly (ADP-ribose) polymerase (PARP) is a nuclear enzyme
involved in the cellular response to DNA injury [5]. Upon
encountering DNA strand breaks, PARP catalyzes the cleav-
age of nicotinamide adenine dinucleotide (NAD+) into nicoti-
namide and ADP-ribose and then uses the latter to synthesize
polymers of ADP-ribose in DNA repair [6]. However, under
conditions of severe DNA injury, overactivation of PARP
severely depletes the intracellular stores of NAD+, slowing the
rate of glycolysis, mitochondrial respiration, and high-energy
phosphate generation, ultimately leading to cell death via the
necrotic pathway [7]. This 'suicide mechanism' is closely
related to the pathogenesis of disease in several pathophysio-
logic conditions of inflammation, and PARP inhibition or inac-
tivation was shown to be protective against the development
of inflammation due to cellular necrosis [8]. On the other hand,
there is accumulating experimental evidence that suggests
that PARP plays a role in nuclear factor-kappa-B (NF-κB)-
dependent transcription and thus contributes to the synthesis
of inflammatory mediators [9,10]. In studies of acute lung injury
(ALI) by various causes, PARP was shown to play a pivotal role
in the pathogenesis of lung injury and PARP inhibitors have
therapeutic effects [11-14]. However, such findings have not
been replicated in studies concerning the development of VILI,
induced directly by an injurious ventilation strategy [15,16].
The purpose of this study was to examine the role of injurious
MV strategy in PARP activation and the effects of a PARP
inhibitor, in the mouse VILI model of normal lung, under the
hypothesis that PARP overactivation may participate in inflam-
matory and transcriptional mechanisms of VILI.
Materials and methods
Animals and mechanical ventilation
The experimental methods were approved by the animal
research committee of Korea University and the ethics com-
mittee of Korea University Medical Center. Five-week-old spe-
cific pathogen-free male C57BL/6 mice, each weighing 20 to
25 g, were randomly divided into the following four experimen-
tal groups: (a) sham tracheostomized group (sham group, n =
18); (b) LPV group (n = 18), in which the mice were ventilated
with low tidal volume (VT) and positive end-expiratory pressure
(PEEP); (c) VILI group (n = 18), in which the mice were venti-
lated with high VT without PEEP; and (d) VILI with PJ34 pre-
treatment group (PJ34+VILI group, n = 18), in which the mice
were pretreated with the PARP inhibitor PJ34 and ventilated
with the same settings as in the VILI group. Each group was
subdivided into three experimental subgroups: (a) tissue sub-
group (n = 6) for histopathologic examination and measure-
ments of wet-to-dry (W/D) weight ratio and PARP activity
assay; (b) bronchoalveolar lavage (BAL) subgroup (n = 6) for
myeloperoxidase (MPO) activity assay and measurements of
inflammatory cytokine concentration and nitric oxide (NO)
metabolites in BAL fluid (BALF); and (c) tissue homogenate
subgroup (n = 6) for measurement of NF-κB activity in lung tis-
sue homogenates.
Each mouse was anesthetized with an intraperitoneal injection
of 65 mg/kg of pentobarbital sodium and intubated via trache-
ostomy. MV was performed with a rodent ventilator (Harvard
Apparatus, Holliston, MA, USA). The mice in the LPV group
were ventilated with a peak inspiratory pressure (PIP) of 15 cm
H2O, a PEEP of 3 cm H2O, and a respiratory rate of 90 breaths
per minute. Adequate setting for the VILI model has been
determined by preliminary studies using various MV settings.
Histopathologic examination of the lung tissues every 30 min-
utes allowed determination of the time and setting that yielded
typical pathological findings of VILI [17]. The typical indica-
tions developed under the following setting: PIP 40 cm H2O +
PEEP 0 cm H2O + 90 breaths per minute. These changes
were most prominent after about 2 hours of MV. Therefore, the
VILI and PJ34+VILI groups were ventilated at this setting for 2
hours, and the LPV group mice were also ventilated for 2
hours. PIP and VT were measured and monitored using a linear
pneumotach (series 8430; Hans Rudolph, Inc., Shawnee, KS,
USA) and research pneumotach system (model RSS 100 HR;
Hans Rudolph, Inc.). Changes in dynamic compliance (CD)
between the beginning and after 2 hours of MV were calcu-
lated from the VT, PIP, and PEEP: CD = VT/(PIP - PEEP). To
maintain deep anesthesia, half of the initial dose of pentobar-
bital sodium was administered after 1 hour of MV.
Tissue preparation, wet-to-dry weight ratio, and 
bronchoalveolar lavage
After MV, the tissue subgroup mice were rapidly exsanguin-
ated by dissecting the abdominal aorta. The heart and lungs
were removed en bloc through a midsternal incision. After liga-
tion of the left main and right upper bronchi, the left lung was
excised, embedded in optimal cutting temperature compound
(Tissue-Tek®; Sakura Finetechnical Co., Ltd., Tokyo, Japan) in
a cryomold, and stored at -70°C for PARP activity assay.
Excised right upper lobe was weighed in a tared container and
dried in an oven until a constant weight was obtained, and the
W/D weight ratio was calculated. The remnant of the right lung
was immediately instilled with 4% paraformaldehyde through
the right main bronchus at a hydrostatic pressure of 15 cm
H2O and fixed in 4% paraformaldehyde for 48 hours. Paraffin
blocks were prepared by dehydration with ethanol and embed-
ding in paraffin.Available online http://ccforum.com/content/12/4/R108
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For the BAL subgroup mice, the thorax was opened following
euthanasia by exsanguination, and three BAL procedures
were performed, each with 1 mL of phosphate-buffered saline
(PBS). The retrieval fluid was centrifuged (2,000 g at 4°C) for
10 minutes and the supernatants were divided into aliquots
and stored at -70°C until analysis for MPO activity and meas-
urements of inflammatory cytokine concentration and NO.
Evaluation of degree of ventilator-induced lung injury
The posterior portions of the right lower lobe were sectioned
at a thickness of 5 μm, placed on glass slides, and stained with
hematoxylin-eosin. A pathologist blinded to the protocol and
experimental groups examined the degree of lung injury and
graded the specimens by ALI score based on (a) alveolar cap-
illary congestion, (b) hemorrhage, (c) infiltration or aggregation
of neutrophils in the airspace or the vessel wall, and (d) thick-
ness of the alveolar wall/hyaline membrane formation. Each
item was graded according to the following five-point scale: 0,
minimal damage; 1, mild damage; 2, moderate damage; 3,
severe damage; and 4, maximal damage [18]. The degree of
VILI was assessed by the sum of scores for items 0 to 16 in
five randomly selected high-power fields (HPFs) (×400). The
average of the sum of each field score was compared among
groups.
PARP activity assay and administration of PARP 
inhibitor
PARP activity in lung tissues was measured by using an immu-
nohistochemical method of PARP activity using biotinylated
NAD+, the substrate of the PARP [12,19]. Briefly, cryosec-
tions of 10 μm were fixed for 10 minutes in 95% ethanol at -
20°C and then rinsed in PBS. Sections were permeabilized by
incubation for 15 minutes at room temperature with 1% Triton
X-100 in 100 mM Tris (pH 8.0). A reaction mixture consisting
of 10 mM MgCl2, 1 mM dithiothreitol, and 30 μM biotinylated
NAD+ in 100 mM Tris (pH 8.0) was then applied to the sec-
tions for 30 minutes at 37°C. Reaction mixtures containing
PJ34 or without biotinylated NAD+ were used as controls.
After three washes in PBS, incorporated biotin was detected
with peroxidase-conjugated streptavidin (1:100 for 30 min-
utes at room temperature). After three 10-minute washes in
PBS, color was developed with cobalt-enhanced nickel-DAB
substrate. Sections were counterstained in Nuclear Fast Red
(Vector Laboratories, Burlingame, CA, USA), dehydrated, and
mounted in Vectamount (Vector Laboratories). PARP activity
was quantified by summing the numbers of cells positive for
PARP activity in five HPFs.
The mice in the PJ34+VILI group were intraperitoneally pre-
treated with 20 mg/kg of PJ34 [N-(6-oxo-5,6-dihydrophen-
anthridin-2-yl)-N,N-dimethylacetamide, hydrochloride]
(Calbiochem, Darmstadt, Germany), which is not antioxidant
and does not directly interfere with the reactivity of peroxyni-
trite [20], and there are no reports that it has an independent
inhibitory effect on NF-κB. The dose was proven to be effec-
tive in lipopolysaccharide (LPS)-induced acute lung inflamma-
tion [12]. To determine optimal pretreatment time, PJ34 was
administered intraperitoneally at each of 24, 12, 6, 4, 3, 2, 1,
and 0.5 hours before MV to six mice at each time. The lowest
PARP activity was observed after 2-hour pretreatment with
PJ34. Thereafter, PARP activity increased at 1 and 0.5 hours.
Therefore, the VILI+PJ34 group mice were pretreated at 2
hours before MV and the mice in the sham, LPV, and VILI
groups were pretreated with 200 μL of PBS 2 hours before
tracheostomy or MV.
BALF analysis and estimation of nuclear factor-kappa-B 
activation in lung tissue homogenates
As an indicator of activated neutrophil accumulation, a major
source of reactive oxygen species (ROS), the activity of MPO
was determined directly in cell-free BALF according to the
method described previously [21], with minor modifications.
Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) in
BALF were measured by enzyme-linked immunosorbent assay
(ELISA) (R&D Systems, Minneapolis, MN, USA). Pulmonary
production of NO was determined by measuring nitrate and
nitrite (NOX), the stable end products of NO metabolism, in the
BALF using an NO (NO2
-/NO3
-) assay kit (Assay Designs, Inc.,
Ann Arbor, MI, USA). Nuclear proteins from the tissue
homogenate subgroup mice were prepared with a nuclear
extract kit (Active Motif, Carlsbad, CA, USA). Activation of the
NF-κB p65 subunit in 5 μg of nuclear extracts was measured
using an NF-κB p65 ELISA-based transcription factor assay
kit (TransAMTM NF-κB p65 Transcriptional Factor Assay Kit;
Active Motif) [22,23].
Statistical analysis
All data are expressed as mean ± standard error of the mean.
Statistical analysis was performed using SPSS for Windows®
(Release 11.0.1; SPSS Inc., Chicago, IL, USA). Intergroup dif-
ferences were determined by nonparametric Mann-Whitney U
and Kruskal-Wallis tests. Statistical significance was defined
as a P value of less than 0.05. Spearman rank correlation coef-
ficient was used to determine the correlations between PARP
activity in the tissues and the other parameters examined.
Results
Expression of PARP and protective effects of PJ34 in 
ventilator-induced lung injury
Histopathologic examination of the VILI group indicated high
levels of ALI parameters (Figure 1c). These findings of lung
injury were markedly reduced in the PJ34+VILI group (Figure
1d). In quantitative comparison by ALI score (Figure 1e), the
VILI group (12.0 ± 0.87) showed a significantly higher score
than the sham and LPV groups (1.20 ± 0.58 and 2.40 ± 0.6,
respectively) (P < 0.05). The score of the PJ34+VILI group
(2.67 ± 0.67) was significantly lower than that of the VILI
group (P = 0.001) and was not different from those of the
sham and LPV groups (P > 0.05). W/D weight ratio (Figure
2a) was also higher in the VILI group (6.28 ± 0.26) than in theCritical Care    Vol 12 No 4    Kim et al.
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Figure 1
Histopathologic findings and acute lung injury (ALI) scores Histopathologic findings and acute lung injury (ALI) scores. The ventilator-induced lung injury (VILI) group (c) showed typical findings of lung injury, 
such as intra-alveolar exudates, hyaline membrane formation, inflammatory cell infiltration, intra-alveolar hemorrhage, and interstitial edema. These 
findings were markedly decreased in the PJ34+VILI group (d). The sham (a) and lung-protective ventilation (LPV) (b) groups were almost normal. 
ALI scores (e) were different among the groups (P < 0.0001 by the Kruskal-Wallis test). The VILI group showed higher ALI scores than the other 
groups (*P < 0.05).
Figure 2
Wet-to-dry (W/D) weight ratio and dynamic compliance (CD) Wet-to-dry (W/D) weight ratio and dynamic compliance (CD). (a) W/D weight ratio was higher in the ventilator-induced lung injury (VILI) group than 
in the other groups (*P < 0.05), and the difference between all groups was significant (P = 0.001 by the Kruskal-Wallis test). (b) CD at the beginning 
of mechanical ventilation (MV) was similar among the lung-protective ventilation (LPV) (), VILI ( ) and PJ34+VILI ( ) groups (P = 0.368 by the 
Kruskal-Wallis test). After 2 hours of MV, CD of the VILI group was lower than those of the other groups (*P < 0.05). CD of the PJ34+VILI group was 
higher than that of the VILI group (**P = 0.021) and lower than that of the LPV group (**P = 0.020) (P = 0.007 by the Kruskal-Wallis test among the 
three groups).Available online http://ccforum.com/content/12/4/R108
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sham and LPV groups (4.60 ± 0.21 and 4.33 ± 0.11, respec-
tively) (P < 0.05). In the PJ34+VILI group, the ratio (5.05 ±
0.32) was significantly decreased relative to that of the VILI
group (P = 0.012) and was similar to those of the sham and
LPV groups (P > 0.05). There were no differences in CDs (Fig-
ure 2b) at the beginning of MV among the LPV, VILI, and
PJ34+VILI groups (0.0314 ± 0.0009, 0.0307 ± 0.0012, and
0.0327 ± 0.0005 mL/cm H2O, respectively) (P  = 0.368,
Kruskal-Wallis test). After 2 hours of MV, however, there were
statistically significant differences between the three groups
(P  = 0.007, Kruskal-Wallis test); the CD of the PJ34+VILI
group (0.0284 ± 0.0006 mL/cm H2O) was significantly higher
than that of the VILI group (0.0244 ± 0.0004 mL/cm H2O) (P
= 0.021) and lower than that of the LPV group (0.0316 ±
0.0004 mL/cm H2O) (P = 0.020).
The PARP activity assay showed large numbers of positively
stained cells in the VILI group (Figure 3c). However, in the
PJ34+VILI group (Figure 3d), the number of cells was
decreased markedly to the levels of the sham (Figure 3a) and
LPV (Figure 3b) groups, in which positively labeled cells were
almost completely absent. The number of cells with PARP
activity in five HPFs (Figure 3e) in the VILI group (108.75 ±
13.185) was greater than in the sham and LPV groups (19.75
± 2.287 and 17.00 ± 7.638, respectively) (P < 0.05). The
number of cells in the PJ34+VILI group (23.50 ± 3.704) was
lower than in the VILI group (P = 0.002), but there were no sta-
tistically significant differences among the sham, LPV, and
PJ34+VILI groups (P > 0.05). In Spearman correlation analy-
sis, PARP activity was positively correlated with the ALI score
(r = 0.950, P < 0.0001) and W/D weight ratio (r = 0.680, P =
0.015) in significance. The CD showed negative correlation
with PARP activity (r = -0.820, P = 0.002).
Correlation of PARP activity with oxidative and 
nitrosative stress and the effects of PJ34
The optical densities (ODs) of the MPO activities in the BALF
(Figure 4a) were significantly higher in the VILI group (0.109 ±
0.006 OD) than the sham (0.076 ± 0.003 OD), LPV (0.076 ±
0.001 OD), and PJ34+VILI (0.089 ± 0.004 OD) groups (P <
0.05). The PJ34+VILI group showed lower activity than the
VILI group (P = 0.035) but higher activity than those of the
sham and LPV groups (P < 0.05). Spearman correlation anal-
ysis showed this activity to be significantly correlated with
PARP activity (r = 0.631, P = 0.004). The concentrations of
NO metabolites nitrate and nitrite (NOX) in BALF (Figure 4b)
were also higher in the VILI group (7.18 ± 0.9 μM) as com-
pared with the other three groups (P < 0.05). The PJ34+VILI
group (3.76 ± 0.76 ìM) showed lower levels than the VILI
group (P = 0.017) and higher levels than the sham and LPV
groups (1.84 ± 0.04 and 1.98 ± 0.31 μM, respectively) (P <
0.05). NOX level was also closely correlated with PARP activity
(r = 0.523, P = 0.026).
Correlations of PARP activity with inflammatory 
cytokines and nuclear factor-kappa-B DNA-binding 
activity and the effects of PJ34
TNF-α was not detected in BALF of the sham group, and IL-6
Figure 3
Poly (ADP-ribose) polymerase (PARP) activity assay Poly (ADP-ribose) polymerase (PARP) activity assay. Larger numbers of positively stained cells were observed in the ventilator-induced lung injury 
(VILI) group (c) than in the other groups. Positive cells were almost completely absent in the sham (a), lung-protective ventilation (LPV) (b), and 
PJ34+VILI (d) groups. The number of cells with PARP activity (e) in five high-power fields (HPFs) (× 400) was higher in the VILI group (*P < 0.05) 
than in the other groups, with significant differences among the four groups (P = 0.002 by the Kruskal-Wallis test).Critical Care    Vol 12 No 4    Kim et al.
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was not detected in the sham and LPV groups. TNF-α concen-
tration (Figure 5a) in the VILI group (14.16 ± 2.533 pg/mL)
was higher than those in the LPV and PJ34+VILI groups (3.24
± 0.416 and 3.58 ± 0.325 pg/mL, respectively) (P < 0.05). IL-
6 concentration (Figure 5b) in the PJ34+VILI group (57.85 ±
Figure 4
Myeloperoxidase (MPO) activity and concentration of nitric oxide (NO) metabolites Myeloperoxidase (MPO) activity and concentration of nitric oxide (NO) metabolites. (a) The optical densities (ODs) of the MPO activities in the bron-
choalveolar lavage fluid (BALF) were different among the groups (P = 0.001 by the Kruskal-Wallis test) and higher in the ventilator-induced lung 
injury (VILI) group than the other three groups (*P < 0.05). The PJ34+VILI group showed higher OD than the sham and lung-protective ventilation 
(LPV) groups (**P < 0.05). (b) The concentration of the NO metabolites nitrate and nitrite (NOX) in BALF was higher in the VILI group as compared 
with the other three groups (*P < 0.05). The level in the PJ34+VILI group was higher than those in the sham and LPV groups (**P < 0.05).
Figure 5
Concentrations of inflammatory cytokines and nuclear factor-κB (NF-κB) DNA-binding activity Concentrations of inflammatory cytokines and nuclear factor-κB (NF-κB) DNA-binding activity. The ventilator-induced lung injury (VILI) group 
showed a higher tumor necrosis factor-alpha concentration (a) than the lung-protective ventilation (LPV) and PJ34+VILI groups (*P < 0.05) and a 
higher concentration of interleukin-6 (b) than the PJ34+VILI group (*P = 0.015). NF-κB DNA-binding activities (c) in lung tissue homogenates were 
higher in the VILI group as compared with the other three groups (*P < 0.05). The PJ34+VILI group showed higher activity than the sham and LPV 
groups (**P < 0.05). ELISA, enzyme-linked immunosorbent assay.Available online http://ccforum.com/content/12/4/R108
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19.499 pg/mL) was lower than that of the VILI group (204.01
± 41.846 pg/mL) (P = 0.015). The concentrations of inflam-
matory cytokines were correlated with PARP activity (r  =
0.691, P = 0.039 for TNF-α; r = 0.699, P = 0.011 for IL-6).
NF-κB DNA-binding activity measured in lung tissue homoge-
nates (Figure 5c) was higher in the VILI group (1.51 ± 0.088
OD) than the sham and LPV groups (0.28 ± 0.056 and 0.17
± 0.014 OD, respectively) (P < 0.05). However, NF-κB DNA
binding in the PJ34+VILI group (0.91 ± 0.189 OD) was lower
than that in the VILI group (P = 0.009) and higher than those
in the sham and LPV groups (P < 0.05). NF-κB activity was
positively correlated with those of PARP (r  = 0.734, P  =
0.001) and the inflammatory cytokines (r = 0.668, P = 0.035
for TNF-α; r = 0.806, P = 0.005 for IL-6).
Discussion
Although the LPV strategy is useful in reducing VILI in patients
with ARDS [3], it is not always possible because of highly het-
erogeneous lung injury in some patients [4]. To develop alter-
native therapeutic strategies directed at preventing VILI, it is
necessary to understand the precise mechanisms involved in
inflammatory reactions in lung injury. PARP, which has been
known to play important roles in inflammation and NF-κB-
dependent transcription, is worthy of investigation in the
pathogenesis of VILI. PARP is a protein-modifying and nucle-
otide-polymerizing enzyme that is abundant in the nucleus and
involves in DNA repair resulting from genotoxic stress by poly
(ADP-ribosyl)ation [24]. However, in the case of excessive
DNA damage, massive PARP activation leads to energy failure
followed by necrotic cell death [24]. This mechanism and the
protective effects of PARP inhibitors have also been reported
to play important roles in the cases of ALI induced by LPS
[12], sepsis [14], acute pancreatitis [13], bleomycin [11], burn
and smoke inhalation [25], hyperoxia [26], ischemia reper-
fusion [27], and hyperoxia [28]. However, until recently, the
role of PARP activation has not been elucidated in severe
inflammatory lung injury of VILI. The present study demon-
strated that PARP overactivated in the development of his-
topathological lung injury, pulmonary edema, and the
worsening of pulmonary mechanics induced by injurious MV
strategy. These changes were significantly correlated with
PARP activity, and pretreatment with PARP inhibitor
decreased the enzyme activity and reduced the injuries, sug-
gesting a pivotal role of PARP in the pathogenesis of VILI.
Recently, Vaschetto and colleagues [29] reported the effect of
PARP inhibitor in the rat model in which MV was performed
after intratracheal LPS instillation. This model is clinically rele-
vant in studying the mechanism of ventilator-associated lung
injury, which refers to the additional injury imposed on a previ-
ously injured lung by MV in either the clinical setting or exper-
imental studies [15,16], but intratracheal administration of
LPS has been reported to induce PARP overactivation in the
lung tissue [12]. Therefore, this model might have limitations in
examining the roles of stretch and shearing injury itself in
PARP activation. It would be difficult to determine whether
PARP is activated by LPS, injurious MV setting, or both and
whether the PARP inhibitor exerts its effect by inhibition of
PARP from LPS, injurious MV setting, or both. The primary
purpose of our study was to investigate the roles of stretch
and shearing forces by injurious MV in PARP activation using
the VILI model of healthy animals. Through this model, we
could examine and conclude that the injurious MV itself could
induce the PARP activation and the PARP inhibitor could pro-
tect the injury by PARP activation, regardless of primary insult
of ALI.
ROS, a major cause of lung injury, is an important trigger of
DNA damage and PARP activation [8]. Although recently ROS
has been reported to be produced by repetitive mechanical
stretching [30-34] and shearing stresses [35-38] in cultured
endothelial cells, ROS originate primarily from activated neu-
trophils. In the present study, oxidative stress from activated
neutrophils was measured indirectly by MPO activity in BALF
and the activity was increased in the VILI group and closely
associated with PARP activity. In the presence of 'oxidative
stress', another reactive species NO reacts rapidly with free
radicals produced by activated neutrophils – superoxide – to
yield peroxinitrite, a labile and toxic oxidant species and the key
pathophysiologically relevant triggers of DNA single-strand
breakage [39]. In the setting of ALI, airspace NO is derived pri-
marily from the inducible form of NO synthase (NOS2), which
can be induced in activated neutrophils either by stimulation
with proinflammatory cytokines or by high VT [40]. Despite the
absence of direct measurement of peroxynitrite in this experi-
ment, the increased level of the NOX due to injurious MV could
yield peroxynitrite by reaction with increased ROS, along with
PARP activity, and inhibition of PARP reduced MPO activity
and NOX level. Injurious MV upregulates pulmonary cytokine
production, which may result in an inflammatory reaction that
aggravates lung injury. Most alveolar cells are capable of pro-
ducing proinflammatory mediators when stretched in vitro or
when ventilated with a large VT in ex vivo and in vivo experi-
ments [41]. On the other hand, NF-κB plays a central role as
a common messenger in cytokine regulation and inflammation.
In experimental models, blockage of NF-κB decreases VILI
[42-44]. NF-κB activation is a critical step in the transcription
of genes necessary in perpetuating the innate immune
response that ultimately results in activation and extravasation
of neutrophils and other immune cells, a process that starts
within minutes after commencement of MV [41]. Recent stud-
ies have shown that PARP regulates the expression of various
proteins at the transcriptional level. NF-κB is a key transcrip-
tion factor in the regulation of this set of proteins, and PARP
has been shown to act as a coactivator in NF-κB-mediated
transcription and thus contributes to the synthesis of inflam-
matory mediators [9,10,45]. There is no consensus in the liter-
ature regarding whether the modulation of NF-κB-mediated
transcription by PARP is dependent on the catalytic activity of
the enzyme or its physical presence [10,46-48]. Similar to
other studies, we showed that injurious MV strategiesCritical Care    Vol 12 No 4    Kim et al.
Page 8 of 9
(page number not for citation purposes)
increased the concentrations of TNF-α and IL-6 in BALF and
NF-κB activity in lung tissue homogenates. These changes
were closely related to PARP activity. The PARP inhibitor
reduced NF-κB activity and inflammatory cytokine concentra-
tions, which were correlated with PARP activity. These results
suggest the transcriptional modulation of PARP in inflamma-
tory lung injury during VILI. To clarify whether transcriptional
modulation is dependent on the catalytic activity of the enzyme
or on its physical presence, experiments with PARP knockout
mice are necessary. The lack of such data is a major limitation
of this study, and the higher activity of NF-κB of the PJ34+VILI
group than the sham and LPV groups suggests that NF-κB is
activated by complex mechanisms other than PARP. Another
limitation is the omission of PJ34+sham and PJ34+LPV
groups. Although PJ34 has been reported to exert its effect
predominantly by inhibition of PARP activity, it would be nec-
essary to experiment with PJ34+sham and PJ34+LPV groups
in order to rule out the effects of PJ34 other than PARP inhibi-
tion in the VILI model.
Conclusion
Overactivation of PARP plays an important role in the inflam-
matory and transcriptional mechanisms of the pathogenesis of
VILI. A clearer understanding of the action mechanisms of
PARP and modulation of its effects may be clinically useful in
the prevention and treatment of VILI in ARDS patients.
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